

Attorney Docket No.: **DEX-0532**
Inventors: **Macina et al.**
Serial No.: **10/523,834**
Filing Date: **April 26, 2006**
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claims 1-18 (canceled)

Claim 19 (currently amended): An isolated monoclonal antibody, or antigen-binding portion thereof, which competes for binding to the epitope bound by an antibody which specifically binds an antigenic region of SEQ ID NO: 265 wherein the antigenic region to which the antibody specifically binds is selected from the group consisting of:

- (a) amino acid residues 59-65 of SEQ ID NO: 265;
- (b) amino acid residues 71-83 of SEQ ID NO: 265;
- (c) amino acid residues 90-97 of SEQ ID NO: 265;
- (d) amino acid residues 130-141 of SEQ ID NO: 265;
- (e) amino acid residues 169-177 of SEQ ID NO: 265;
- (f) amino acid residues 186-193 of SEQ ID NO: 265;
- (g) amino acid residues 195-202 of SEQ ID NO: 265;

and

(h) ~~an antigenic region comprising~~ amino acid residues 226-240 of SEQ ID NO: 265.

Claim 20 (canceled)

Claim 21 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is a humanized antibody.

Attorney Docket No.: **DEX-0532**
Inventors: **Macina et al.**
Serial No.: **10/523,834**
Filing Date: **April 26, 2006**
Page 4

Claim 22 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is a chimeric antibody.

Claim 23-24 (canceled)

Claim 25 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is labeled.

Claim 26 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 19 wherein the antibody, or antigen-binding portion thereof, is conjugated to a toxin.

Claim 27 (currently amended): An isolated monoclonal antibody, or antigen-binding portion thereof, which specifically binds an antigenic region of SEQ ID NO: 265 wherein the antigenic region to which the antibody specifically binds is selected from the group consisting of:

- (a) amino acid residues 59-65 of SEQ ID NO: 265;
- (b) amino acid residues 71-83 of SEQ ID NO: 265;
- (c) amino acid residues 90-97 of SEQ ID NO: 265;
- (d) amino acid residues 130-141 of SEQ ID NO: 265;
- (e) amino acid residues 169-177 of SEQ ID NO: 265;
- (f) amino acid residues 186-193 of SEQ ID NO: 265;
- (g) amino acid residues 195-202 of SEQ ID NO: ~~26~~ 265;

and

(h) ~~an antigenic region comprising~~ amino acid residues 226-240 of SEQ ID NO: 265.

Attorney Docket No.: **DEX-0532**
Inventors: **Macina et al.**
Serial No.: **10/523,834**
Filing Date: **April 26, 2006**
Page 5

Claim 28 (canceled)

Claim 29 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is a humanized antibody.

Claim 30 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is a chimeric antibody.

Claim 31-32 (canceled)

Claim 33 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is labeled.

Claim 34 (previously presented): The antibody, or antigen-binding portion thereof, of Claim 27 wherein the antibody, or antigen-binding portion thereof, is conjugated to a toxin.

Claims 35-42 (canceled)